Is the business good?
How good a business is EYPT?
EyePoint, Inc. keeps −3701% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−3701%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- R&D as % of revenue
- 3081%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −108% |
| FY2021 | −150% |
| FY2022 | −241% |
| FY2023 | −163% |
| FY2024 | −337% |
| FY2025 | −776% |
Details›
- Operating margin12 months to Q1 2026
- −3701%
- Net margin12 months to Q1 2026
- −3567%
- Free cash flow margin
- −3566%
- R&D as % of revenue
- 3081%
- Revenue, trailing twelve months
- $7.6M
- Free cash flow, trailing twelve months
- −$272M
- Net income, trailing twelve months
- −$272M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.